Basilea Pharmaceutica (OTCMKTS:BPMUF) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Thursday, Zacks.com reports.

According to Zacks, “Basilea Pharmaceutica Ltd. is a commercial stage biopharmaceutical company developing products that address the medical challenge of increasing resistance and non-response to current treatment options in the therapeutic areas of bacterial infections, fungal infections and cancer. With two commercialized drugs, the company is committed to discovering, developing and commercializing innovative pharmaceutical products to meet the medical needs of patients with serious and life-threatening conditions. “

Shares of BPMUF stock remained flat at $$50.20 on Thursday. The stock’s 50 day moving average is $52.61 and its 200-day moving average is $56.11. Basilea Pharmaceutica has a 1 year low of $49.00 and a 1 year high of $61.00. The company has a market capitalization of $539.18 million, a PE ratio of -24.02 and a beta of 1.50.

About Basilea Pharmaceutica

Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers Cresemba, an intravenous and oral azole antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, the European Union, and internationally, as well as in Phase III clinical trials for invasive fungal infections in Japan.

Read More: What are no-load funds?

Get a free copy of the Zacks research report on Basilea Pharmaceutica (BPMUF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Basilea Pharmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basilea Pharmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.